Assignee profile:

Takeda GmbH

City:

Constance

Country:

Germany

Published Applications:

35

Last publication date:

2021-09-16

Patent Grants:

35

Last grant date:

2021-11-23

Top Inventors for applications by Takeda GmbH

These are the the leading inventors for applications assigned to Takeda GmbH:

Recent patent applications by Takeda GmbH

Takeda GmbH based in Constance, DE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2021-09-16 ✅ Patent 11,179,384 granted on 2021-11-23
US20210283122A1
Human necessities

Treatment of nonalcoholic fatty liver disease

#2 | 2021-04-22 ✅ Patent 11,690,839 granted on 2023-07-04
US20210113549A1
Human necessities

Treatment of idiopathic pulmonary fibrosis

#3 | 2018-07-26 ✅ Patent 10,758,621 granted on 2020-09-01
US20180207278A1
Human necessities

Liquid formulation comprising GM-CSF neutralizing compound

#4 | 2017-09-07 ✅ Patent 11,173,208 granted on 2021-11-16
US20170252436A1
Human necessities

Liquid formulation comprising GM-CSF neutralizing compound

#5 | 2017-06-22 ✅ Patent 10,495,630 granted on 2019-12-03
US20170176416A1
Physics

Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions

#6 | 2016-12-08 ✅ Patent 10,745,475 granted on 2020-08-18
US20160355584A1
Chemistry; metallurgy

Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics

#7 | 2016-09-29 ✅ Patent 9,962,377 granted on 2018-05-08
US20160279120A1
Human necessities

Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

#8 | 2015-12-03 ✅ Patent 9,833,410 granted on 2017-12-05
US20150342888A1
Human necessities

Lyophilized formulation comprising GM-CSF neutralizing compound

#9 | 2015-04-30 ✅ Patent 9,149,479 granted on 2015-10-06
US20150119389A1
Human necessities

Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

#10 | 2015-03-19 ✅ Patent 9,309,187 granted on 2016-04-12
US20150080400A1
Chemistry; metallurgy

EP2 receptor agonists

#11 | 2015-03-19 ✅ Patent 9,545,490 granted on 2017-01-17
US20150075527A1
Human necessities

Apparatus for the aerosolization of large volumes of dry powder

#12 | 2014-12-25 ✅ Patent 9,090,597 granted on 2015-07-28
US20140378509A1
Chemistry; metallurgy

Pyrazolone derivatives as PDE4 inhibitors

#13 | 2014-03-13 ✅ Patent 8,883,818 granted on 2014-11-11
US20140073636A1
Chemistry; metallurgy

Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

#14 | 2014-02-06 ✅ Patent 8,829,189 granted on 2014-09-09
US20140039001A1
Chemistry; metallurgy

Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives

#15 | 2013-09-05 ✅ Patent 8,618,142 granted on 2013-12-31
US20130231374A1
Chemistry; metallurgy

Process for the preparation of roflumilast

#16 | 2013-08-29 ✅ Patent 8,604,064 granted on 2013-12-10
US20130224299A1
Human necessities

Process for the preparation of roflumilast

#17 | 2013-04-18 ✅ Patent 8,754,218 granted on 2014-06-17
US20130096152A1
Chemistry; metallurgy

Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives

#18 | 2013-01-10 ✅ Patent 8,865,745 granted on 2014-10-21
US20130012544A1
Chemistry; metallurgy

Pyrazolone derivatives as PDE4 inhibitors

#19 | 2012-11-15 ✅ Patent 9,018,175 granted on 2015-04-28
US20120289474A1
Chemistry; metallurgy

3,4,4a,10b-Tetrahydro-1H-thiopyrano-[44,3-c] isoquinoline derivatives

#20 | 2012-10-04 ✅ Patent 8,440,210 granted on 2013-05-14
US20120247982A1
Human necessities

Stabilized pharmaceutical product

#21 | 2012-04-19 ✅ Patent 8,910,627 granted on 2014-12-16
US20120090606A1
Human necessities

Apparatus for the aerosolization of large volumes of dry powder

#22 | 2011-11-03 ✅ Patent 8,541,456 granted on 2013-09-24
US20110269750A1
Human necessities

Roflumilast for the treatment of diabetes mellitus type 2

#23 | 2011-10-13 ✅ Patent 8,431,154 granted on 2013-04-30
US20110251244A1
Human necessities

Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient

#24 | 2011-09-08 ✅ Patent 8,609,848 granted on 2013-12-17
US20110218201A1
Chemistry; metallurgy

Pyrazolone-derivatives and their use as PDE-4 inhibitors

#25 | 2011-07-14 ✅ Patent 8,758,817 granted on 2014-06-24
US20110171303A1
Human necessities

Dosage form containing (S)-pantoprazole as active ingredient

#26 | 2011-04-21 ✅ Patent 8,486,923 granted on 2013-07-16
US20110092471A1
Human necessities

Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis

#27 | 2011-01-27 ✅ Patent 8,445,501 granted on 2013-05-21
US20110021479A1
Chemistry; metallurgy

Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines

#28 | 2010-01-14 ✅ Patent 8,481,516 granted on 2013-07-09
US20100009951A1
Human necessities

Ciclesonide containing sterile aqueous suspension

#29 | 2009-08-20 ✅ Patent 8,703,192 granted on 2014-04-22
US20090208571A1
Human necessities

Dosage form containing pantoprazole as active ingredient

#30 | 2009-04-09 ✅ Patent 8,754,108 granted on 2014-06-17
US20090093522A1
Human necessities

Freeze-dried pantoprazole preparation and pantoprazole injection

#31 | 2008-09-18 ✅ Patent 8,465,767 granted on 2013-06-18
US20080226712A1
Human necessities

Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles

#32 | 2007-11-08 ✅ Patent 9,205,044 granted on 2015-12-08
US20070259009A1
Human necessities

Aqueous pharmaceutical preparation comprising roflumilast

#33 | 2007-02-01 ✅ Patent 8,464,707 granted on 2013-06-18
US20070023034A1
Human necessities

Compliance monitor and method

#34 | 2006-06-15 ✅ Patent 9,422,327 granted on 2016-08-23
US20060128954A1
Chemistry; metallurgy

Process for preparing crystalline ciclesonide with defined particle size

#35 | 2006-06-15 ✅ Patent 8,435,497 granted on 2013-05-07
US20060127323A1
Human necessities

Formoterol of and ciclesonide combination

Also check out Takeda GmbH's (Constance, Germany) applicant profile with 20 patent applications submitted.

AssigneeID:

464716 ⎘